Core Insights - RxSight, Inc. reported a total revenue of $33.6 million for Q2 2025, a 4% decrease from $34.9 million in Q2 2024, with LAL revenue increasing by 13% and LDD revenue decreasing by 50% [4][10] - The company aims to accelerate growth through enhanced customer engagement and strategic expansion of its installed base, supported by a newly launched Customer Success Organization [3] Financial Performance - Gross profit for Q2 2025 was $25.2 million, representing 74.9% of revenue, an increase from $24.3 million or 69.5% of revenue in Q2 2024 [5] - Total operating expenses for Q2 2025 were $39.2 million, a 20% increase from $32.6 million in Q2 2024, reflecting investments in LAL sales and R&D [6] - The net loss for Q2 2025 was $(11.8) million, or $(0.29) per share, compared to a net loss of $(6.1) million, or $(0.16) per share in Q2 2024 [7] Cash Position - Cash, cash equivalents, and short-term investments decreased by $1.8 million to $227.5 million as of June 30, 2025, compared to $229.3 million as of March 31, 2025 [8] Guidance - The company reiterated its 2025 full-year revenue guidance of $120.0 million to $130.0 million, indicating a decrease of 14% to 7% compared to 2024 [9][14]

Core Viewpoint - RxSight, Inc. has announced preliminary financial results for Q2 2025, indicating a decrease in revenue and a revised full-year guidance, while also focusing on enhancing customer success and engagement with clinical partners [1][3]. Preliminary Second Quarter 2025 Results - Preliminary revenue for Q2 2025 is expected to be approximately $33.6 million, a decrease of 4% year-over-year and an 11% decrease compared to Q1 2025 [8]. - The company sold 27,380 Light Adjustable Lenses (LAL®/LAL+®), reflecting a 1% decrease in procedure volume from Q1 2025 but a 13% increase from Q2 2024 [8]. - The sale of 40 Light Delivery Devices (LDD™s) saw a significant decline, with a 45% decrease compared to Q1 2025 and a 49% decrease compared to Q2 2024 [8]. - As of June 30, 2025, the installed base of LDDs increased to 1,084, a 34% growth from 810 LDDs at the end of Q2 2024 [8]. Revised 2025 Guidance - Full-year revenue guidance has been revised downward to a range of $120.0 million to $130.0 million, a decrease from the previous range of $160.0 million to $175.0 million, implying a decrease of 14% to 7% compared to 2024 [9]. - Gross margin guidance has been increased to a range of 72% to 74%, up from the previous range of 71% to 73%, representing an increase of 130 to 330 basis points compared to 2024 [9]. - Operating expense guidance is set between $145.0 million and $155.0 million, indicating an increase of 7% to 14% compared to 2024, which includes non-cash stock-based compensation expenses estimated between $27.0 million and $30.0 million [9].

Core Insights - RxSight, Inc. reported a strong financial performance for Q1 2025, with total revenue reaching $37.9 million, a 28% increase from $29.5 million in Q1 2024, driven by significant growth in Light Adjustable Lens (LAL) sales [4][9] - The company continues to emphasize the clinical value of its Light Adjustable Lens, which is gaining traction among cataract surgeons, and believes that customization and post-operative adjustability will be key trends in premium cataract surgery [3][9] Financial Performance - Total revenue for Q1 2025 was $37.9 million, up 28% from $29.5 million in Q1 2024, with LAL revenue increasing by 37% and Light Delivery Device (LDD) revenue rising by 8% [4][9] - Gross profit for Q1 2025 was $28.3 million, representing 74.8% of revenue, an increase from $20.7 million or 70.1% of revenue in Q1 2024, attributed to lower cost of sales and a favorable product mix [5][9] - Operating expenses for Q1 2025 totaled $39.0 million, a 24% increase from $31.4 million in Q1 2024, reflecting investments in LDD and R&D [6][9] - The net loss for Q1 2025 was $(8.2) million, or $(0.20) per share, an improvement from a net loss of $(9.1) million, or $(0.25) per share in Q1 2024 [7][9] Guidance and Market Position - The company reiterated its full-year 2025 revenue guidance of $160.0 million to $175.0 million, indicating growth of 14% to 25% compared to 2024 [10] - Gross margin is expected to be in the range of 71% to 73%, while operating expenses are projected to be between $150.0 million and $160.0 million, reflecting a 10% to 18% increase compared to 2024 [10][11] - RxSight sold 27,579 LALs in Q1 2025, a 36% increase in procedure volume compared to the same period in 2024, and expanded its installed base of LDDs to 1,044, a 43% increase year-over-year [9][10]